More recently, vaccination with WT1 peptide-loaded dendritic cells combined with targeted therapy or conventional chemotherapy demonstrated safety and feasibility in advanced RCC and bladder cancer patients [88]. The gene discussed is WT1; the disease is urinary bladder cancer.